Northland Capital Markets Upgrades Protagonist Therapeutics (PTGX) to Outperform
Tweet
Share
E-mailGet Alerts PTGX Hot Sheet
Price: $151.42 --0%
Rating Summary:
20 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 9
Rating Summary:
20 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 9
Join SI Premium – FREE
Northland Capital Markets analyst Tim Chiang upgraded Protagonist Therapeutics (NASDAQ: PTGX) from Market Perform to Outperform with a price target of $40.00 (from $25.00).
For an analyst ratings summary and ratings history on Protagonist Therapeutics click here. For more ratings news on Protagonist Therapeutics click here.
Shares of Protagonist Therapeutics closed at $18.24 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Upgrades FOX Corp. (FOXA) to Overweight
- Goldman Sachs Upgrades Protagonist Therapeutics (PTGX) to Buy
- Northland Upgrades Hyliion Holdings (HYLN) to Outperform 'on Improved Visibility to KARNO Commercialization'
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
